Table 3.
Adjusted and PS-matched RR of 30-day all-cause hospitalization or facility-reported mortality by diagnosis month
| Diagnosis month | High-risk sotrovimab, no. (%)a | High-risk no mAb, no. (%)a | RRb,c (95% CI) | PS-matched RRb,d (95% CI) | P-valuee |
|---|---|---|---|---|---|
| September 2021 | 460 (4.78) | 307,096 (9.53) | 0.48 (0.32, 0.72) | 0.39 (0.26, 0.60) | < 0.001 |
| October 2021 | 451 (2.66) | 84,367 (8.62) | 0.29 (0.17, 0.51) | 0.27 (0.15, 0.47) | < 0.001 |
| November 2021 | 1232 (2.76) | 119,829 (7.81) | 0.33 (0.23, 0.45) | 0.32 (0.22, 0.45) | < 0.001 |
| December 2021 | 5188 (3.14) | 455,706 (3.90) | 0.49 (0.43, 0.57) | 0.45 (0.39, 0.53) | < 0.001 |
| January 2022 | 4859 (1.85) | 261,765 (3.37) | 0.36 (0.30, 0.44) | 0.36 (0.29, 0.44) | < 0.001 |
| February 2022 | 2329 (3.26) | 103,346 (6.90) | 0.43 (0.34, 0.54) | 0.40 (0.32, 0.50) | < 0.001 |
| March 2022 | 1046 (2.01) | 65,521 (4.37) | 0.41 (0.27, 0.62) | 0.36 (0.23, 0.56) | < 0.001 |
| April 2022 | 68 (1.47) | 117,238 (1.90) | 0.54 (0.08, 3.54) | 0.32 (0.04, 2.38) | 0.519 |
PS propensity score, RR relative risk, mAb monoclonal antibody, CI confidence interval
aThe reported % = number hospitalized or died in diagnosis month in treatment cohort/number in diagnosis month in treatment cohort
bReference group = high-risk no mAb
cAdjusted for diagnosis month category, age, gender, region, rurality, high-risk conditions, and documented COVID-19 vaccine
d15,633 sotrovimab patients were matched with 62,532 no mAb patients on diagnosis month, age, gender, region, rurality, and selected high-risk conditions
eP-value applies to RR and PS-matched RR